文献速递垂体与肾上腺疾病性腺与生殖内分泌

经典型与非经典型21-羟化酶缺陷症患者未经治疗下的生存情况

Survival without treatment of patients with classic and non-classic 21-hydroxylase deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2026-07-28

本多中心回顾性开放队列研究描述了经典型(失盐型29例、单纯男性化型23例)和非经典型(24例)21-羟化酶缺陷症患者未经糖皮质激素治疗下的生存情况。经典型患者中48%从未接受治疗,其中71%在未治疗期间未发生肾上腺危象;非经典型患者中21%从未治疗,8.3%发生肾上腺危象。

要点

  • 经典型21OHD患者中近半数从未接受糖皮质激素治疗。
  • 未治疗的经典型患者中71%未发生肾上腺危象。
  • 非经典型患者肾上腺危象发生率低,且多在7岁前发生。

核心结论

  • 部分经典型和非经典型21OHD患者可在未接受糖皮质激素治疗的情况下长期生存,且多数未发生肾上腺危象。

研究设计与样本

  • 多中心回顾性开放队列观察性研究,纳入经典型(失盐型29例、单纯男性化型23例)和非经典型(24例)21OHD患者。

主要发现

  • 经典型患者未治疗时间中位8.7年(IQR 4.7-14.3),非经典型为28.1年(IQR 12.2-39.0),组间p<0.001。
  • 经典型患者中48%从未接受糖皮质激素治疗,其中71%在未治疗期间未发生肾上腺危象,即使患病或接受手术干预时也未发生。
  • 非经典型患者中21%从未接受糖皮质激素治疗,2例(8.3%)发生肾上腺危象,均为I2剪接/P31L基因型。
  • 除1例外,所有肾上腺危象均报告发生于7岁前。

临床怎么用

  • 对21OHD患者需个体化评估糖皮质激素治疗的必要性,部分患者可能无需持续治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is characterized by cortisol and aldosterone deficiency and hyperandrogenism. Historically, patients have been classified into salt-wasting (SW), simple-virilizing (SV), and the less severe non-classic (NC) form. Standard treatment for patients with classic 21OHD (SW and SV) consists of glucocorticoid and sometimes mineralocorticoid replacement to prevent adrenal crises. Interestingly, some patients were untreated due to delayed diagnosis or stopped treatment and survived without overt signs of adrenal insufficiency. OBJECTIVE: Describe a cohort of patients with 21OHD who survived without glucocorticoid treatment, with particular focus on sickness, surgical interventions, and adrenal crises. DESIGN: Observational study. SETTING: Multicenter retrospective open cohort study. PATIENTS: Patients with classic (SW, n=29; SV, n=23) and NC (n=24) 21OHD, with a median age of 11.0 and 21.7 years, respectively. RESULTS: Patients with classic and NC 21OHD were untreated with glucocorticoid for 8.7 years (IQR 4.7-14.3) and 28.1 years (IQR 12.2-39.0), respectively (p<0.001). Of patients with classic 21OHD, 48% never received glucocorticoid treatment. Remarkably, 71% of them did not experience adrenal crises during the untreated period, even during illness or surgical interventions. In the NC 21OHD group, 21% was never treated with glucocorticoid, two patients (8.3%) experienced an adrenal crisis, both had an I2 splice/P31L genotype. All adrenal crises, except one, were reported before the age of 7 years. CONCLUSIONS: Study on untreated patients with 21OHD provides valuable opportunity to further explore mechanisms that influence glucocorticoid activity and elucidate disease variability in 21OHD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Adriaansen BPH, Utari A, Chandra EA, et al. Survival without treatment of patients with classic and non-classic 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2026. PMID: 42517590. doi:10.1210/clinem/dgag298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。